O
Optolane
Semiconductor-based digital real-time PCR diagnostic platforms
About Optolane
Optolane is a South Korean company founded in 2012 that develops and manufactures in-vitro diagnostic (IVD) platforms based on semiconductor technology. The company's core technology integrates complementary metal-oxide-semiconductor (CMOS) sensors with optical and thermal control systems to create compact, rapid, and high-sensitivity diagnostic devices. This technology is applied to its main product line of digital real-time Polymerase Chain Reaction (PCR) systems, which combine the features of both real-time PCR and digital PCR, allowing for simultaneous real-time amplification tracking and absolute quantification of nucleic acids.
The company's product portfolio includes the 'LOAA' analyzer and associated cartridges, which are designed for professional use in medical institutions and research laboratories. These systems are used for a variety of applications, including liquid biopsy for cancer diagnosis, infectious disease detection, gene expression analysis, and copy number variation. For example, the 'Genotizer' product, a Real-Time digital PCR (RT-dPCR) platform, can detect a single cancer cell among 100 million to 1 billion cells, significantly improving diagnostic accuracy for early cancer detection and treatment monitoring. Optolane also produces multiplex real-time PCR systems like the 'Genoplexor,' capable of diagnosing up to 16 targets simultaneously with a turnaround time of about 30 minutes to an hour.
The business operates in the diagnostic equipment market, providing what it terms "sample-to-answer" solutions. Its offerings are notable for their reduced size and weight, a direct result of embedding key functions onto a semiconductor chip. In 2020, the company developed a digital real-time PCR kit for COVID-19 diagnosis, leveraging its chip-embedded technology for faster results. The CEO, Lee Do-young, previously founded the fabless image sensor manufacturer Siliconfile, which was later acquired by SK hynix. The company has raised at least $74 million in funding from investors including UTC Investment, Wonik Investment Partners, and Solidus Investment.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jul 2023 | $36M | $142M | Undisclosed | ↗ |
| OtherOther financing | Jan 2022 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Optolane is 3.8K monthly website visits, up 11.8% over the last three months. Optolane's team declined 3.7% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Genomictree
Other known investors4 additional known investors
- BIBNH Investment
Partners Investment
UTC Investment
WONIK Investment Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Optolane on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Optolane’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.